Merck

Few safe havens surface in another down quarter for biopharma
EP Vantage
Fri, 10/14/22 - 10:03 am
biopharma stocks
COVID-19
Eli Lilly
Bristol Myers Squibb
Merck
Daiichi Sankyo
Vertex Pharmaceuticals
Takeda
Neurocrine
Sarepta Therapeutics
Orion
Pfizer
GSK
Roche
Moderna Therapeutics
BeiGene
BioNTech
Novavax
CureVac
Merck and Moderna Move Forward with Personalized Cancer Vaccine
BioSpace
Wed, 10/12/22 - 11:35 pm
Merck
Moderna Therapeutics
vaccines
mRNA-4157/V940
melanoma
Royalty Pharma bets Merck's schizophrenia drug can go where Pfizer, Takeda and Lundbeck's couldn’t
Endpoints
Wed, 10/12/22 - 10:55 am
Merck
Royalty Pharma
schizophrenia
MK-8189
Ginkgo Scores Another Big Partner in Merck Biocatalyst Deal
BioSpace
Tue, 10/11/22 - 10:38 am
Ginkgo Bioworks
Merck
biocatalysts
APIs
drug manufacturing
Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy
Fierce Biotech
Mon, 10/10/22 - 11:06 am
Merck
Acceleron
clinical trials
sotatercept
PAH
pulmonary arterial hypertension
Merck Covid antiviral pill did not cut hospitalization risk, study finds
Financial Times
Sun, 10/9/22 - 06:08 pm
Merck
COVID-19
molnupiravir
Merck KGaA says it'll consider 'larger-scale' acquisitions from 2023 onward
Fierce Pharma
Thu, 10/6/22 - 07:08 pm
Merck
KGaA
M&A
Merck's $500M bet on Singapore leads to new manufacturing sites making Keytruda, Gardasil and future inhalers
Endpoints
Thu, 10/6/22 - 10:38 am
Merck
Singapore
drug manufacturing
Merck celebrates another win in Januvia patent battle against Viatris
Endpoints
Sun, 10/2/22 - 07:46 pm
Merck
Januvia
patents
legal
diabetes
Viatris
Keytruda taught Merck how to build a blockbuster. But manufacturing a 2nd lightning bolt is easier said than done
Fierce Pharma
Thu, 09/29/22 - 07:42 pm
Merck
Keytruda
cancer
oncology
ESMO
Seagen, amid deal rumors, spends $50M on a dual-targeting cancer drug
BioPharma Dive
Mon, 09/26/22 - 11:20 pm
Seagen
Merck
Lava Therapeutics
bispecific antibodies
LAVA-1223
AstraZeneca, Merck withdraw Lynparza's late-line ovarian cancer nod amid PARP inhibitor death concerns
Fierce Pharma
Sun, 09/25/22 - 02:28 pm
AstraZeneca
Merck
Lynparza
ovarian cancer
Merck pulls a patent win for diabetes franchise in West Virginia federal court
Endpoints
Thu, 09/22/22 - 11:12 pm
Merck
Januvia
Janumet
generics
legal
Viatris
Merck finally gets FDA nod to relaunch HIV trials, but drops preventive therapy plans
Fierce Biotech
Tue, 09/20/22 - 10:26 am
Merck
FDA
clinical trials
islatravir
Seagen secures a speedy FDA review on Tukysa as Merck buyout talks reportedly stall
Endpoints
Mon, 09/19/22 - 10:02 pm
Seagen
Merck
M&A
Tukysa
Bristol Myers' Opdivo win tees up showdown with Keytruda in earlier-stage melanoma
Fierce Pharma
Thu, 09/15/22 - 11:15 pm
Merck
Keytruda
Bristol Myers Squibb
Opdivo
melanoma
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
Fierce Pharma
Mon, 09/12/22 - 10:57 am
ESMO
Roche
Bristol Myers Squibb
kidney cancer
Keytruda
Merck
Opdivo
Yervoy
ESMO: Merck's Keytruda chalks up failure in head and neck cancer. But experts see silver lining
Fierce Pharma
Mon, 09/12/22 - 10:52 am
Merck
Keytruda
head and neck cancer
ESMO
ESMO: Seagen's Padcev pulls its weight in combo with Merck's Keytruda
Fierce Pharma
Thu, 09/8/22 - 04:40 pm
Merck
Keytruda
Astellas
Seagen
Padcev
ESMO
urothelial cancer
ESMO 2022 – the new liver cancer entrants line up
EP Vantage
Thu, 09/8/22 - 10:39 am
ESMO
liver cancer
Keytruda
tislelizumab
camrelizumab
Merck
BeiGene
Novartis

Pages